PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 17, 2018

Primary Completion Date

August 30, 2019

Study Completion Date

October 7, 2019

Conditions
HealthyContraceptionContraceptive UsageWomen
Interventions
DRUG

VR: 200 mg DPV + 320 mg LNG

One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)

Trial Locations (1)

15213

Magee-Women'S Res Inst and Foundation, Pittsburgh

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

Division of AIDS, US National Institute of Allergy and Infectious Diseases

UNKNOWN

collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

International Partnership for Microbicides, Inc.

INDUSTRY

NCT03467347 - PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel | Biotech Hunter | Biotech Hunter